ATE404192T1 - Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration - Google Patents

Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration

Info

Publication number
ATE404192T1
ATE404192T1 AT01958395T AT01958395T ATE404192T1 AT E404192 T1 ATE404192 T1 AT E404192T1 AT 01958395 T AT01958395 T AT 01958395T AT 01958395 T AT01958395 T AT 01958395T AT E404192 T1 ATE404192 T1 AT E404192T1
Authority
AT
Austria
Prior art keywords
nefiracetam
neurodegeneration
postischemic
treat
stroke
Prior art date
Application number
AT01958395T
Other languages
English (en)
Inventor
Eiichi Otomo
Yoshiyuki Takasu
Original Assignee
Hamilton Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamilton Pharmaceuticals Inc filed Critical Hamilton Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE404192T1 publication Critical patent/ATE404192T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT01958395T 2001-08-22 2001-08-22 Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration ATE404192T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2001/007180 WO2003018005A1 (en) 2001-08-22 2001-08-22 use of nefiracetam for treating neurodegeneration

Publications (1)

Publication Number Publication Date
ATE404192T1 true ATE404192T1 (de) 2008-08-15

Family

ID=11737657

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01958395T ATE404192T1 (de) 2001-08-22 2001-08-22 Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration

Country Status (8)

Country Link
US (2) US20040192759A1 (de)
EP (1) EP1420782B1 (de)
JP (1) JP2005501108A (de)
AT (1) ATE404192T1 (de)
CA (1) CA2457982C (de)
DE (1) DE60135390D1 (de)
ES (1) ES2311537T3 (de)
WO (1) WO2003018005A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
RU2329804C2 (ru) * 2006-03-28 2008-07-27 Валентина Ивановна Ахапкина Вещество, обладающее нейротропной - нейромодуляторной активностью
AU2009303834B2 (en) 2008-10-16 2016-08-11 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2664727T3 (es) 2009-10-22 2018-04-23 University College Dublin National University Of Ireland, Dublin Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP
CN102905532A (zh) * 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
JP3388778B2 (ja) * 1991-05-02 2003-03-24 第一製薬株式会社 脳血管性痴呆改善剤
CA2067614C (en) * 1991-05-02 2002-07-30 Eiichi Otomo Agent for improving dementia
ATE266401T1 (de) * 1997-07-15 2004-05-15 Daiichi Seiyaku Co Nefiracetam zur prophylaxe und behandlung von propofol verursachtem gedächtnisschwund
JPH1180027A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
US6423739B1 (en) * 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration

Also Published As

Publication number Publication date
JP2005501108A (ja) 2005-01-13
US20040192759A1 (en) 2004-09-30
CA2457982C (en) 2009-11-03
EP1420782B1 (de) 2008-08-13
ES2311537T3 (es) 2009-02-16
US20080076820A1 (en) 2008-03-27
DE60135390D1 (de) 2008-09-25
EP1420782A1 (de) 2004-05-26
CA2457982A1 (en) 2003-03-06
WO2003018005A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
DE69918296D1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
BR0311313A (pt) Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
ATE157871T1 (de) Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
BR0104586A (pt) Método para tratamento de neurodegeneração
HUP0402092A2 (hu) 2-[5-(4-Fluorfenil)-3-piridilmetilaminometil]-kromán vegyületek és fiziológiásan elfogadható sói alkalmazása gyógyszerkészítmények előállítására
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
DE602004025103D1 (de) Heilkräuterzusammensetzung zur Behandlung von AIDS
DE68916651T2 (de) Heilmittel zur behandlung von toxoplasmose.
ATE491474T1 (de) Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
EA200501591A1 (ru) Фармацевтическая комбинация для лечения мышечной спастичности и/или боли
RU2000125000A (ru) Состав для антисептической обработки кожи рук и операционного поля
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck
RU2003135700A (ru) Способ лечения хирургической инфекции

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties